<DOC>
	<DOCNO>NCT02897349</DOCNO>
	<brief_summary>To evaluate efficacy safety linagliptin compare placebo add insulin therapy alone combination metformin Chinese patient type 2 diabetes mellitus insufficient glycaemic control</brief_summary>
	<brief_title>Linagliptin Add-on Insulin Background Therapy</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Inclusion criterion : Diagnosis type 2 diabetes mellitus prior inform consent . Chinese male female patient pretreated insulin alone combination metformin : With maximum insulin dose &lt; = 1 unit/kg/day . Acceptable basal insulin could insulin glargin , insulin detemir NPH ( neutral protamin hagedorn ) insulin duration action 24 h ; acceptable premixed insulin could preparations 25/75 30/70 ratio , twice daily posology . The total insulin dose change 10 % baseline value within 12 week prior randomisation ( Visit 3 ) . Both human insulin &amp; insulin analogue accept . If patient take metformin , stable dose ( least 1500 mg daily ) must maintain least 12 week without dose adjustment prior randomisation ( Visit 3 ) . HbA1c fulfill follow criterion : &gt; = 7.5 % &lt; = 10.0 % Visit 1 . Age &gt; = 18 year Visit 1 . BMI &lt; = 45 kg/m2 ( Body Mass Index ) Visit 1 . Women childbearing potential must ready able use highly effective method birth control per ICH ( International Conference Harmonisation ) M3 ( R2 ) result low failure rate le 1 % per year use consistently correctly . A list contraception method meet criterion provide patient information . A woman consider childbearing potential ( WOCBP ) , i.e . fertile , follow menarche become postmenopausal unless permanently sterile . Permanent sterilisation method include hysterectomy , bilateral salpingectomy bilateral oophorectomy . Signed date write informed consent date Visit 1 accordance ICHGCP ( Good Clinical Practice ) local legislation Exclusion criterion : Uncontrolled hyperglycaemic glucose level &gt; 240 mg/dl ( &gt; 13.3 mmol/L ) overnight fast placebo runin confirm second measurement ( day ) . Any antidiabetic drug within 3 month prior inform consent except define background treatment via inclusion criterion 2 . Acute coronary syndrome ( nonSTEMI ( ST Segment Elevation Myocardial Infarction ) , STEMI unstable angina pectoris ) , stroke TIA ( Transient ischemic attack ) within 3 month prior inform consent . Indication liver disease , define serum level either ALT ( Alanine aminotransferase ) ( SGPT ( serum glutamic pyruvate transaminase ) ) , AST ( Aspartate aminotransferase ) ( SGOT ( serum glutamicoxaloacetic transaminase ) ) , alkaline phosphatase 3 Ã— upper limit normal ( ULN ( upper limit normal ) ) determine screen and/or runin phase . Any contraindication metformin accord local label patient enter study metformin therapy provide ISF ( Investigator Site File ) . Bariatric surgery within past two year gastrointestinal surgery induce chronic malabsorption . Medical history cancer ( except basal cell carcinoma ) and/or treatment cancer within last 5 year . Blood dyscrasia disorder cause hemolysis unstable Red Blood Cell ( e.g . malaria , babesiosis , haemolytic anemia ) . Known hypersensitivity allergy investigational product recipient . Treatment antiobesity drug 3 month prior inform consent treatment time screen ( i.e . surgery , aggressive diet regimen , etc . ) lead unstable body weight . Current treatment systemic steroid time informed consent change dosage thyroid hormone within 6 week prior inform consent uncontrolled endocrine disorder except T2DM ( Type 2 diabetes mellitus ) . Women pregnant , nursing , plan become pregnant trial . Alcohol drug abuse within 3 month prior inform consent would interfere trial participation ongoing condition lead decrease compliance study procedure study drug intake opinion investigator . Participation another trial investigational drug within 2 month prior inform consent previous enrolment trial . Any clinical condition would jeopardize patient 's safety participate clinical trial opinion investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>